Assessment of Price Changes of Existing Tumor Necrosis Factor Inhibitors After the Market Entry of Competitors.

Authors :: San-Juan-Rodriguez A
Prokopovich MV
Shrank WH
Good CB
Hernandez I
Source :: JAMA internal medicine [JAMA Intern Med] 2019 May 01; Vol. 179 (5), pp. 713-716.
Publication Year :: 2019

Subjects :: Adalimumab economics
Antibodies, Monoclonal economics
Arthritis, Rheumatoid drug therapy
Certolizumab Pegol economics
Drug Approval
Drug Costs
Etanercept economics
Health Expenditures
Humans
Infliximab economics
Medicare Part D
Tumor Necrosis Factor Inhibitors therapeutic use
United States
Costs and Cost Analysis
Drug Industry
Tumor Necrosis Factor Inhibitors economics

Full Text Access

Tools